The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.

The present invention provides a method for determining whether or not all of pythiums contained in a test sample are non-phytopathogenic. The method comprises: (a) putting the test sample on a front surface of a film comprising a through-hole having a cross-sectional area of not less than 0.785 square micrometers and not more than 7.065 square micrometers; (b) leaving the test sample at rest after the step (a); (c) observing a back surface of the film after the step (b); and (d) determining that all of the pythiums contained in the test sample are non-phytopathogenic, if pseudohyphae are not found on the back surface of the film in the step (c).

The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.

The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.

Molecules compounds are provided having the structure in Formula I, or a salt thereof, wherein n1 is independently 0, 1, 2, or 3; n.sup.2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; n.sup.3 is from 0, 1, 2, or 3; n.sup.4 is 0 or 1; and n.sup.5 is 0, 1, 2, or 3; and wherein X is O, N, or S; Y, Z, XX, and YY are the same or different and are independently O or S; ZZ comprises nitrogen, oxygen, sulfur, or selenium; and wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 are as described herein. Methods are also provided for the synthesis of and use of the provided molecules in applications for diagnostic testing.

A transgenic corn event, Zm_CSM63715, is provided. Transgenic plant cells, plant parts, plants, seeds, progeny plants, and agricultural and commodity products containing event Zm_CSM63715 are also provided. Recombinant DNA molecules unique to the event Zm_CSM63715, and methods of using and detecting Zm_CSM63715 are also provided. Corn plants containing the event Zm_CSM63715 exhibit tolerance to PPO inhibitors.

Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. The microbe-targeting or microbe-binding molecules can comprise a microbe surface-binding domain linked to a portion of an Fc region. Further, the microbe-targeting molecules can be conjugated to substrate (e.g., a magnetic particle) to form a microbe-targeting substrate. Such microbe-targeting molecules and/or substrates and the kits comprising the same can be used in various applications, such as diagnosis and/or treatment of an infection caused by microbes. Moreover, the microbe-targeting molecules and/or substrates can be easily regenerated after use.

The present invention relates to a device for detecting a fungal contamination in an internal environment, to the use thereof and also to a method for detecting a fungal contamination in an internal environment using such a device.

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to -glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti--glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti--glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti--glucan antibody.

The present invention provides a hybridoma cell under the accession number CGMCC No. 13827. The hybridoma cell is capable of producing a monoclonal antibody against Aspergillus galactomannan antigen and a kit is prepared using the same. The kit provided by the present invention can specifically bind to the GM antigen, has both sensitivity and specificity of more than 95%, a detection limit of 0.85 ng/mL compared to 1 ng/mL of the existing product, and high compliance rate between the detection result and the reference reagent, and can provide more accurate and reliable detection results, so that IA can be detected early in the course of the disease and the patients can receive treatment in timely and effective manner, thereby improving the survival rate of patients. Moreover, the kit has simple and convenient operation, rapid and sensitive detection, which provides an effective tool for the quantitative detection of Aspergillus GM antigen.